The tolerability and clinical efficacy of “OKOMISTIN” in combination with “Oftalmoferon” in comparison to “Oftalmoferon” as monotherapy in the treatment of adenoviral eye diseases

Astakhov, Yury S.; Сергеевич, Астахов Юрий; Sokolov, Vitaly Olegovich; Олегович, Соколов Виталий; Morozova, Natalia Vladimirovna; Владимировна, Морозова Наталья; Borisov, Dmitrii Alexandrovich; Александрович, Борисов Дмитрий; Polovinkina, Galina Viktorovna; Викторовна, Половинкина Галина; Golikova, Yelena Leonidovna; Леонидовна, Голикова Елена; Botova, Natal’ya Viktorovna; Викторовна, Ботова Наталья

doi:10.17816/ov2013451-54

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На фоне систематических инстилляций Офтальмоферона с периодичностью 6-8 и Окомистина -4 раза в день полное купирование клинических признаков конъюнктивита имело место на 9,6 сутки терапии, а на фоне закапываний лишь Офтальмоферона с той же кратностью -на 12,9 суток. Вместе с тем авторами отмечено развитие вторичного синдрома «сухого глаза», причем более часто (71 %)в основной группе больных, получавших комплексную терапию с использованием Окомистина, чем на фоне монотерапии Офтальмофероном (42 %) [20]. Указанные обстоятельства следует учитывать при назначении рассматриваемого препарата больным с воспалительными заболеваниями глаз.…”

Section: Introductionunclassified

New Possibilities of Antibiotic Therapy in Pediatric and Adult Ophthalmology

et al. 2019

View full text Add to dashboard Cite

The problems of resistance to modern antibiotics and fluoroquinolones naturally stimulate interest in the development of eye dosage forms based on antiseptics. Today, their list has successfully supplemented the domestic drug Okomistin eye, ear, nasal drops (0.01 % — benzyldimethyl-myristoylamino-propylammonium), the manufacturer of Infamed-K. Numerous clinical studies performed, however, on adult patients, indicate a high therapeutic efficacy of the drug Okomistin®. However, with respect to children, the efficacy of Okomistin® remains unclear, although the drug has been approved for use by children from birth today.Objective. To evaluate the effectiveness of the Okomistin® in the treatment of children with bilateral bacterial conjunctivitis.Patients and Methods. Material research consisted of 30 children aged 3–16 years with bilateral acute bacterial conjunctivitis. 15 of them (26 eyes) received six-time instillations of the Okomistin® and 15 (24) — 0.05 % — Рicloxidin. All were subjected to traditional clinical examination and examination of the microflora of the conjunctival cavity with the determination of its sensitivity to antibiotics using the disk method.Results. In the spectrum of microflora found in the examined children, Staphylococcus Аureus dominated (14 eyes (53.8 %) — in the group of patients receiving Okomistin® and 13 (54.2 %) — Picloxidin), and Еpidermal Staphylococcus — 12 (46, 2 %) and 12 (50.0 %), respectively. Against the background of six-fold instillations of the compared drugs, a pronounced positive dynamics was established in relation to the relief of objective and subjective clinical symptoms of bacterial conjunctivitis already in the first week of treatment. At the same time, on the 7th day of therapy, in both groups of children, a significant decrease in the frequency of detection of microflora in the conjunctival cavity was noted, and on the 10th day, all the examined people underwent the contents of the conjunctival cavity to be sterile.Conclusion. The clinical efficacy of the Okomistin®, in combination with the absence of side effects of the drug and the affordable cost, allows recommending it for widespread practical use in pediatric and adult ophthalmology in the treatment of eye diseases of a bacterial nature. It seems promising to study the effectiveness of the drug in order to reorganize the conjunctival cavity in infants with dacryocystitis.

show abstract

Section: Introductionunclassified

New Possibilities of Antibiotic Therapy in Pediatric and Adult Ophthalmology

et al. 2019

View full text Add to dashboard Cite

show abstract

Ocular surface viral diseases in children

Маркова

Полунина

Na³

et al. 2016

Vestn. oftal'mol.

View full text Add to dashboard Cite

In case of viral infections, ophthalmologists, pediatricians and general practitioners should all be aware of ocular manifestations of these diseases. Even if adequate therapy for ocular surface viral disorders is appointed, in five percent of cases complications are possible, causing decline in visual function. Changes in vision can be a result of general disease manifestation, and only timely and proper treatment will help to relieve the symptoms of inflammation and prevent complications.The results of our observations revealed that the addition of Ophtalmoferon medication to the complex therapy of ocular surface diseases in children showed a high therapeutic efficacy and a good safety profile. This medication, in contrast to other antiviral agents, is available in the form of ready-to-use eye drops, significantly enhancing medication compliance in outpatients.

show abstract

The tolerability and clinical efficacy of “OKOMISTIN” in combination with “Oftalmoferon” in comparison to “Oftalmoferon” as monotherapy in the treatment of adenoviral eye diseases

Cited by 2 publications

References 0 publications

New Possibilities of Antibiotic Therapy in Pediatric and Adult Ophthalmology

New Possibilities of Antibiotic Therapy in Pediatric and Adult Ophthalmology

Ocular surface viral diseases in children

Contact Info

Product

Resources

About